Streetbeat News

Products Services

BIOL

Biolase has completed a trial program for its Waterlase iPlus All Tissue Laser, receiving unanimously positive feedback from dentists. The trial results showed 100% performance satisfaction and a recommendation for broader adoption in dental practices.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 9:12 pm

FTEK

Fuel Tech, a leader in air pollution control and chemical technologies, has received orders totaling $2.5 million from clients in South Africa and the Caribbean. These orders are for Fuel Tech's advanced pollution control solutions and chemical technologies, which are designed to help reduce emissions and improve air quality.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 9:11 pm

COLD

Americold Realty Trust, Inc. (NYSE:COLD) has announced a joint venture with RSA Cold Chain and DP World to build a $35 million cold storage facility in Dubai. The facility, with 40,000 pallet positions, will be located in the Jebel Ali Free Zone and is expected to be operational by Q1 of 2025. This investment is part of Americold's strategic expansion in the Middle East and India, aiming to triple Dubai's current capacity to over 70,000 pallet positions. The collaboration with DP World began in 2021 and was formalized in November 2022, enhancing Americold's global temperature-controlled infrastructure and DP World's logistics solutions.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 9:11 pm

CREV

Carbon Revolution plc (NASDAQ: CREV), a manufacturer of carbon fiber wheels, reported a 56% year-over-year increase in fiscal Q1 2024 revenue to $11.3 million. The company expects continued growth with a Q2 revenue forecast of $14M-$14.5M, driven by doubling its backlog to $730 million, with 50% for EVs. The company is focused on profitable growth through automation and increased production volume.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 9:09 pm

RSLS

ReShape Lifesciences has received FDA PMA Supplement Approval for its next-generation Lap-Band 2.0 FLEX. The company is gearing up for the U.S. launch of the product and plans to provide updates on its progress.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 9:09 pm

CRBU

Caribou Biosciences announced that it has met with the FDA and reached an agreement on the design of a pivotal Phase 3 trial for its treatment. The FDA has accepted the proposed comparator arm involving platinum-based immunochemotherapy, HDCT, and ASCT. Caribou plans to initiate the Phase 3 trial by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 9:04 pm

AI

AMD

CAVA

NVDA

TSLA

Retail traders on Reddit's r/WallStreetBets are focusing on several tech stocks, including AMD, TSLA, CAVA, NVDA, and AI. AMD announced new AI accelerator chips and saw a 16% stock increase over five days. TSLA gained 10% over the past month, with a reiterated Outperform rating and $310 price target from Wedbush. CAVA shares rose after the IPO lockup period ended without selling pressure. NVDA dipped after soaring most of the year, with U.S. export controls scrutiny. AI shares fell 8% post-earnings with lowered analyst price targets.

Portfolio Pulse from Erica Kollmann

December 12, 2023 | 9:03 pm

ETHUSD

Former President Donald Trump has launched a third collection of NFTs, the 'MugShot Edition,' which includes digital and physical trading cards, some containing pieces of the suit he wore in his mug shot from an arrest. The NFTs are priced at $99 and can be purchased with credit cards or Wrapped Ethereum (WETH). The collection has 100,000 digital collectibles, a significant increase from previous releases. Buyers of 47 NFTs will receive a physical card and an invitation to a dinner gala at Mar-a-Lago. The suit was authenticated by MEARS, a sports memorabilia authenticator. The NFTs cannot be transferred until December 31, 2024. Trump's previous NFT collections have seen value increases post-launch, with the first collection's floor price at 0.12 ETH and the second at 0.0315 ETH.

Portfolio Pulse from Chris Katje

December 12, 2023 | 8:33 pm

INCY

Incyte Corporation (NASDAQ:INCY) stock has seen a significant increase, rising approximately 13% since Monday. The surge follows a period of consolidation over November and comes after the company's third-quarter financial results and 2023 net product revenue guidance. Additionally, the stock's price target has varied between $63 to $98 in the past month. The recent spike is attributed to the announcement of full results from the Phase 2 AGAVE-201 trial of axatilimab, presented at the American Society of Hematology Annual Meeting 2023. At the time of publication, INCY shares were up 8.75% at $62.03.

Portfolio Pulse from Ryan Gustafson

December 12, 2023 | 8:33 pm

NFLX

Netflix has publicly released viewership data for all its shows and films for the first time, providing transparency into the popularity of its content. This move could help Netflix attract new talent and partnerships by showcasing the success of its platform.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 7:31 pm